Cargando…
Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn’s Disease
Treatment with Anti-Tumor Necrosis Factor (anti-TNF) therapy has become a mainstay of therapy for patients with CD who are unresponsive to conventional medical management. Currently there are three anti-TNFα antibodies that have been approved by the US Food and Drug Administration for the treatment...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Libertas Academica
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987757/ https://www.ncbi.nlm.nih.gov/pubmed/24833930 http://dx.doi.org/10.4137/CGast.S7613 |